Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults
about
New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.Tetanus toxin fragment C fused to flagellin makes a potent mucosal vaccine.Anthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunityGeneration and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine.Immunization with a Recombinant, Pseudomonas fluorescens-Expressed, Mutant Form of Bacillus anthracis-Derived Protective Antigen Protects Rabbits from Anthrax InfectionStochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralizationAnthrax lethal toxin and the induction of CD4 T cell immunity.Anthrax vaccines: present status and future prospects.Anthrax Vaccine Precipitated induces Edema Toxin-neutralizing, Edema Factor-specific antibodies in human recipients.Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.Protein- and DNA-based anthrax toxin vaccines confer protection in guinea pigs against inhalational challenge with Bacillus cereus G9241.
P2860
Q34066161-96999CC1-3BF7-456B-81F7-F4680EB03640Q35035621-D869D7D5-FC9D-4287-9057-7877FAA0E10CQ35161514-9BC54864-4E8E-48C9-893C-FEC1DDCD36C4Q35548062-106544BB-1BFF-4C17-BC2F-E3FB68C172FFQ35710981-612CF844-7DD3-4EE4-BFDE-D3D215966F1FQ36733960-50402DA9-A301-425E-BECA-BB965490B23CQ38060730-3CD170E8-736F-4AA5-88A9-E866177C7874Q38132268-1788ACD2-5601-41E7-AA3F-493C6E35F927Q40064017-FC7A3516-D161-49BA-9B3F-AA5BDEA8E879Q40213025-0C495341-A746-4F10-BF35-92076591DED9Q46943316-26FB97BC-46E5-471D-BCD4-6EF5399556C9
P2860
Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase I study of safety and im ...... e to prevent anthrax in adults
@ast
Phase I study of safety and im ...... e to prevent anthrax in adults
@en
type
label
Phase I study of safety and im ...... e to prevent anthrax in adults
@ast
Phase I study of safety and im ...... e to prevent anthrax in adults
@en
prefLabel
Phase I study of safety and im ...... e to prevent anthrax in adults
@ast
Phase I study of safety and im ...... e to prevent anthrax in adults
@en
P2093
P2860
P50
P1433
P1476
Phase I study of safety and im ...... e to prevent anthrax in adults
@en
P2093
Anita Gillis
Bruce K Brown
Karen Metcalfe
Kelly T McKee
Lindsay Wieczorek
Mark Milazzo
Mary Marovich
Raburn M Mallory
Tanya Santelli Antonille
Thomas C VanCott
P2860
P304
P356
10.1371/JOURNAL.PONE.0013849
P407
P577
2010-11-05T00:00:00Z